Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor by Katz, Steven C et al.
 
Anti-KIT designer T cells for the treatment of gastrointestinal
stromal tumor
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Katz, Steven C, Rachel A Burga, Seema Naheed, Lauren A
Licata, Mitchell Thorn, Doreen Osgood, Cang T Nguyen, N
Joseph Espat, Jonathan A Fletcher, and Richard P Junghans.
2013. Anti-kit designer t cells for the treatment of
gastrointestinal stromal tumor. Journal of Translational Medicine
11:46.
Published Version doi:10.1186/1479-5876-11-46
Accessed February 19, 2015 12:00:56 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10785358
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH Open Access
Anti-KIT designer T cells for the treatment of
gastrointestinal stromal tumor
Steven C Katz
1*, Rachel A Burga
1, Seema Naheed
1, Lauren A Licata
1, Mitchell Thorn
1, Doreen Osgood
1,
Cang T Nguyen
1, N Joseph Espat
1, Jonathan A Fletcher
3 and Richard P Junghans
2
Abstract
Background: Imatinib mesylate is an effective treatment for metastatic gastrointestinal stromal tumor (GIST).
However, most patients eventually develop resistance and there are few other treatment options. Immunotherapy
using genetically modified or designer T cells (dTc) has gained increased attention for several malignancies in
recent years. The aims of this study were to develop and test novel anti-KIT dTc engineered to target GIST cells.
Methods: Human anti-KIT dTc were created by retroviral transduction with novel chimeric immune receptors (CIR).
The gene for stem cell factor (SCF), the natural ligand for KIT, was cloned into 1
st generation (SCF-CD3ζ, 1st gen)
and 2
nd generation (SCF-CD28-CD3ζ, 2nd gen) CIR constructs. In vitro dTc proliferation and tumoricidal capacity in
the presence of KIT+ tumor cells were measured. In vivo assessment of dTc anti-tumor efficacy was performed by
treating immunodeficient mice harboring subcutaneous GIST xenografts with dTc tail vein infusions.
Results: We successfully produced the 1
st and 2
nd gen anti-KIT CIR and transduced murine and human T cells. Average
transduction efficiencies for human 1
st and 2
nd gen dTc were 50% and 42%. When co-cultured with KIT+ tumor cells,
both 1
st and 2
nd gen dTc proliferated and produced IFNγ. Human anti-KIT dTc were efficient at lysing GIST in vitro
compared to untransduced T cells. In mice with established GIST xenografts, treatment with either 1
st or 2
nd gen human
anti-KIT dTc led to significant reductions in tumor growth rates.
Conclusions: We have constructed a novel anti-KIT CIR for production of dTc that possess specific activity
against KIT+ GIST in vitro and in vivo. Further studies are warranted to evaluate the therapeutic potential and
safety of anti-KIT dTc.
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Background
Gastrointestinal stromal tumor (GIST) is the most
common GI mesenchymal neoplasm and nearly all
GIST express KIT (CD117) [1]. Imatinib mesylate has
been demonstrated to significantly prolong disease-free
survival in the adjuvant setting and for patients with
disseminated GIST [2,3]. Unfortunately, the majority of
patients with metastatic GIST who are treated with
imatinib develop resistance and subsequently progressive
disease [4]. Therapeutic options are limited for patients
who develop advanced GIST unresponsive to tyrosine
kinase inhibitor (TKI) therapy. In an effort to address this
clinical need, we sought to develop a Tcell-based therapy
for the treatment of KIT+ tumors including GIST.
Cell-based immunotherapy using tumor infiltrating
lymphocytes (TIL) has shown success for specific
diseases [5]. The potential impact of TIL therapy is
limited by the inability to isolate TIL from the majority
of patients with solid tumors [6]. The genetically modi-
fied or designer T cell (dTc) strategy allows for the pro-
duction of tumor-specific lymphocytes for any patient
with a suitable target tumor antigen. Lymphocytes are
isolated from peripheral blood and activated prior to
retroviral transduction with a chimeric immune receptor
(CIR) gene [7]. Expression of CIR on the surface of
modified T cells allows for highly specific recognition of
tumor cells expressing the cognate antigenic moiety.
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into human T cells has resulted in dTc capable of acti-
vation, cytokine secretion, and target cell lysis [8-10].
Clinical success has recently been reported using dTc
for the treatment of soft tissue sarcoma, melanoma,
and leukemia [11,12]. We are not aware of prior efforts
to treat GIST using dTc.
CIR typically exploit immunoglobulin or T cell recep-
tor based specificity to target tumor antigens. Using an
alternative strategy, we engineered a CIR that contains
the natural ligand for KIT, which allows for recognition
of KIT+ tumor cells. KIT-ligand (KL) or stem cell fac-
tor (SCF) was fused to the CD3ζ chain component of
the T cell receptor (1st generation, 1
st gen) or CD3ζ +
the CD28 co-stimulatory molecule (2nd generation, 2
nd
gen). The 2
nd gen dTc express the construct that targets
KIT+ tumors while, at the same time, integrating
CD28 co-stimulatory signals. 1
st and 2
nd gen dTc were
produced and tested in vitro and in vivo to demonstrate
their efficacy in destroying KIT+ tumor cells. The
present report demonstrates encouraging initial results
for anti-KIT dTc and provides the rationale for further
pre-clinical testing of this novel immunotherapeutic
anti-tumor agent.
Methods
Retroviral vector construction
First and second generation anti-KIT CIR were re-
engineered from the anti-CEA retroviral vector expression
constructs previously described [7]. The extracellular do-
main of cKIT ligand ([Genbank:BC069733.1], cDNA clone
MGC:97379) spanning the N-terminal start codon to the
transmembrane start was PCR amplified from ATCC
clone 010560371 using primers incorporating NcoI and
BamHI restriction sites and cloned in-frame to replace the
anti-CEA extracellular domain.
Extracellular domain of cKIT ligand:
(5’-gattccaggaattgatttccccatggcaaagaagacacaaacttg-3’
5’-ctaagctctagccaattgaattggatccgtgtaggctggagtctcc-3’)
Designer T cell production
Human peripheral blood mononuclear cells (PBMC)
were obtained from random donor whole blood filtrate
(Rhode Island Blood Center, Providence, RI). Blood
filters were washed with sterile PBS (Cellgro, Manassas,
VA) and PBMC were isolated by density gradient separ-
ation with Histopaque (Sigma-Aldrich, St. Louis, MO)
according to manufacturer directions. PBMC were
seeded at a density of 2 × 10
6 cells/ml, and activated on
anti-CD3 coated (OKT3, eBioscience, San Diego, CA)
750 ml flasks with 2 ug/mL anti-CD28 (CD28.2,
eBioscience) and 300 U/mL of human IL-2 in AIM V
medium (Invitrogen, Grand Island, NY) supplemented
with 5% heat inactivated sterile human serum
(Valley Biomedical, Winchester, VA). 293T-HEK phoenix
amphotropic cells (Orbigen, Allele Biotechnology, San
Diego, CA) were transfected with 50 μg1
st or 2
nd gen
c-KIT ligand CIR retroviral plasmid using LipoD283
(SignaGen Laboratories, Rockville, MD). Viral super-
natant was harvested for transduction of NIH-3T3
PG13 retrovirus packaging cells (ATCC: CRL-10686)
cells that had reached 80% confluence. PG13 cells were
cultured at 37°C and supernatant was harvested and
filtered through 0.45 μm filters (Corning, Corning NY)
when cells reached 80% confluence. After 24-48 hours
of culture, PBMC were seeded on retronectin-coated
(20 ug/mL, Takara Bio, Otsu, Shiga, Japan) wells of a
6-well plate and were transduced with viral super-
natant as described to create designer T cells [7].
Cells were transduced with supernatant containing
either anti-KIT CIR vector (1
st gen) or anti-KIT CIR
vector with additional CD28 moiety (2
nd gen).
Transduced T cells were maintained in AIM V
medium supplemented with 5% heat inactivated ster-
ile human serum and 100 IU/ml IL-2. Expression of
KIT-specific CIR on designer T cells was evaluated
by flow cytometric analysis of staining with anti-SCF
mAb (Reprokine, Valley Cottage, NY) conjugated to
APC (Chromaprobe, Maryland Hts, MO). Cells were
also stained with antibodies against human CD3
(Sk7), CD4 (RPA-T4), CD8 (SK1), CD62L, CD45RO,
CD197 (CCR7, 150503), and CD25 (M-A251), which
were conjugated to FITC, PE, PerCP, APC, APC-Cy7,
or Pe-Cy7 (BD Biosciences, Franklin Lakes NJ). For
FoxP3 intracellular staining, samples were fixed,
permeabilized, and stained with FoxP3 conjugated to
PE as per manufacturer’s protocol (BD).
Cell proliferation assay
Flow cytometry-based division assays were performed to
analyze the proliferation of 1st and 2nd gen dTc in re-
sponse to stimulation by KIT+ human GIST cell lines
GIST882 [13] and GIST48, [14] both of which contain
oncogenic KIT mutations. GIST882 was established from
an untreated GIST, whereas GIST48 was established
from a kinase-inhibitor resistant GIST which was
progressing clinically after initial response to imatinib
therapy. DTc were labeled with 1 μM carboxyfluorescein
diacetate succinimidyl ester (CFSE, Invitrogen) and
were added at a 4:1 ratio with KIT+ GIST 882 and
GIST 48 cells in a 96-well round-bottom plate, with 1 ×
10
5 dTc added per well. GIST48B cells [15], which have
minimal KIT surface expression, were used as a nega-
tive control initially. MC38 murine colorectal carcin-
oma cells were also used as negative controls to ensure
complete absence of human KIT on the cell surface.
Tumor cells were irradiated at 5000 rad. Co-culture
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was isolated and cells were analyzed by flow cytometry.
Supernatant was analyzed by cytometric bead array for
IFN-γ levels (BD Biosciences). Cytokine production
results were also quantified by human IFN-γ ELISA
assay for confirmation (Biolegend).
Cytotoxicity assays
1
st and 2
nd gen dTc were cultured with KIT+ GIST 882
or GIST 48 cells in order to evaluate their cytotoxic abil-
ity in an LDH assay (Roche, Indianapolic, IN) performed
according to the manufacturer’s protocol. Tumor cells
were irradiated at 5000 G for 50 minutes. Cytotoxic abil-
ity was evaluated for 1
st gen dTc, 2
nd gen dTc, and
untransduced human T cells, which were added at vari-
ous effector-to-target ratios. Cytotoxicity results from
the LDH assay were further confirmed by flow
cytometric analysis of tumor cell death. GIST cells were
irradiated as previously described and labeled with CFSE
while dTc were unstained; loss of CFSE+ cells was
analyzed with flow cytometry.
In vivo tumor studies
Six-week-old male immunodeficient mice (NU/J) were
purchased from Jackson Laboratories (Bar Harbor, ME)
and experiments were conducted in compliance with
the guidelines of the Roger Williams Medical Center
Institutional Animal Care and Use Committee. The
GIST cell lines were maintained at 37°C in IMDM
with 1% l-glutamine (Invitrogen) supplemented with
15% FBS, and 1% Penicillin/Streptomycin/Amphomycin
(Cellgro). We administered bilateral subcutaneous flank
injections of 3 × 10
7 KIT+ GIST 882 cells in 200 ul
sterile PBS. DTc or untransduced human T cells were
injected (1 × 10
7 in 200 ul PBS) via tail vein. For ex-
perimental groups with IL-2, Alzet 7-day micro-
osmotic pumps (Durcet, Cupertino CA) were filled
with IL-2 according to the manufacturer’s protocol and
implanted subcutaneously. Pumps were set to deliver
at a rate of 10,000 IU/h (550 pg/h). Tumors were
measured in two dimensions with calipers, and
measurements were obtained daily from the time of
T cell injection until the conclusion of the study.
The average of right and left flank tumors was used
for each mouse, and measurements were normalized
to initial tumor size. After sacrifice, tumors were
excised and sent to the University of Massachusetts,
Worchester Medical Center Experimental Pathology
Service Core, for histological sectioning and staining.
Sections were stained for routine H&E and anti-CD3
immunohistochemistry. Slides were analyzed at the
Pathology Department at Roger Williams Medical
Center, and photographs were taken under 10x and
40x magnification.
Statistics
Statistics were calculated using GraphPad Prism V5.00
for Windows (GraphPad Software, San Diego, CA).
Statistical significance for proliferation and cytotox-
icity assays was determined using the two-tailed Stu-
dent t test, and values with p≤0.05 were classified
statistically significant. Tumor size median values are
presented and logistic regression was used to compare
growth curve slope and elevation among groups. Cell
proliferation analysis with calculation of division
peaks was performed using FlowJo software (Treestar,
Ashland, OR).
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Figure 1 Structure of anti-KIT chimeric immune receptor.
(A) Schematic diagram of 1
st and 2
nd generation CIR genetic
constructs. (B) Structure of 1
st and 2
nd generation CIR. Anti-KIT CIRs
were re-engineered from anti-CEA retroviral vector constructs,
whereby the extracellular domain of kit ligand (KL) was amplified
and cloned to replace the anti-CEA extracellular domain.
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Engineering of anti-KIT chimeric immune receptors and
production of designer T cells
Our aim for this study was to construct and test the
function of KIT-specific CIR expressed by human per-
ipheral blood T cells for pre-clinical development. We
based our anti-KIT CIR construct on our pre-existing
anti-CEA format [7]. The anti-CEA sFv fragment was
replaced with the extracellular domain of KL. 1
st and 2
nd
gen constructs were prepared (Figure 1A). The 2
nd gen
construct contains CD28 to provide co-stimulation. The
KL component is expressed on the extracellular aspect
of the CIR to enable interaction with KIT on the surface
of target tumor cells (Figure 1B). We confirmed our
constructs by direct DNA sequencing prior to transduc-
tion of activated lymphocytes (data not shown).
Following activation and transduction, CIR expres-
sion was confirmed by flow cytometry with an anti-KL
antibody. Retroviral transduction of activated murine
splenocytes (not shown), which we used as a prelimin-
ary assessment, resulted in mean 1
st and 2
nd gen CIR
expression rates of 27% (range, 16–41). Following
optimization of our protocol, transduction of activated
human PBMC (Figure 2A) yielded mean transduction
rates of 50% (range, 33-74) and 42% (range, 24–62) for
1
st and 2
nd gen human dTc respectively, with no sig-
nificant difference between the two CIR versions
(p=0.67). After stimulation of PBMC with anti-CD3,
anti-CD28 and IL2, >70% of the cells were CD3+
(data not shown) and a central memory phenotype
(CD45RO+CD62L+ CCR7+) predominated (Figure 2B)
for both CD4+ and CD8+ T cells. Fewer than 30% of
cells had a naïve (CD45RO-CD62L+) or effector mem-
ory (CD45RO+CD62L+CCR7-) phenotype, and less
than 10% of transduced T cells from both generations
had a regulatory T cell phenotype (CD25+FoxP3+) with
no difference between the groups (data not shown). For
1
st gen dTc, 33.4% of T cells were CD4+CD8- and 52.7%
1st gen 2nd gen
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Figure 2 Transduction efficiency and phenotype of human anti-KIT designer T cells (dTc). (A) PBMC were isolated and primary human
T cells activated and transduced with retrovirus expressing KIT-specific CIRs. Shaded histograms represent dTc and open histograms represent
untransduced cells. (B) Flow cytometric analysis of the phenotype of 1
st and 2
nd generation dTc demonstrated that T cells (CD4+ and CD8+
T cells) of a central memory phenotype (CD45RO+CD62L+CCR7+) were in the majority. Naïve T cells were defined as (CD45RO-CD62L+). Data are
representative of three or more repetitions.
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gen dTc were 35.5% and 52.6%. The CD4:CD8 ratio did
not change after transduction or exposure to KIT+
tumor (not shown). For all subsequent experiments, dTc
were used in bulk, without fractionating by CD4 or CD8
expression, in keeping with current clinical practice for
dTc infusions.
Proliferation of anti-KIT dTc in the presence of KIT+
tumor cells
To test the proliferative capacity of human T cells
expressing anti-KIT CIR, we cultured the dTc in the
presence of two human KIT+ GIST cell lines, GIST882
and GIST48 [14,16]. In the presence of GIST882 and
GIST48, dTc expressing either the 1
st or 2
nd gen anti-
KIT CIR proliferated to a greater extent when compared
to control groups (CTRL) as determined by CFSE dilu-
tion (Figure 3A). When cultured with GIST882, 39% of
the 1
st gen and 47% of the 2
nd gen dTc divided (p<0.001
compared to CTRL), with no significant difference be-
tween the two CIR formats (p=0.23, Figure 3B). Like-
wise, in the presence of imatinib resistant GIST48 cells,
33–38% of the dTc divided after 3 days in culture which
was significantly higher than CTRL cells (p≤0.03
compared to CTRL), with no significant difference be-
tween the two CIR formats (p=0.56, Figure 3C). The re-
quirement of KIT+ tumor cells for dTc proliferation was
confirmed by the minimal proliferation that resulted
when culturing dTc in the presence of KIT- GIST 48B
cells, and CIR- activated T cells did not proliferate in the
presence of KIT+ tumor (data not shown). IFNγ produc-
tion confirmed dTc activation by KIT+ tumor and
was found to be in the range of 462-475 pg/ml, while
production by CIR- T cells was negligible (p<0.001,
Figure 3D). Co-culture of anti-KIT dTc with KIT-
control tumor cells did not result in significant IFNγ
production (data not shown).
Lysis of KIT+ tumor cells by anti-KIT designer T cells
The hallmark of effective adoptive cellular immunotherapy
is the ability of the product to lyse tumor cells in a specific
fashion. To this end, we performed in vitro assays to deter-
mine if dTc expressing anti-KIT CIR were able to destroy
GIST cells. We demonstrated that 2
nd gen dTc effectively
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st gen
format by LDH release (Figure 4A). To confirm our
findings, we mixed CFSE-labeled irradiated tumor cells
with unlabeled T cells. Tumor cell loss or death was
measured by quantifying the decrease in CFSE fluores-
cence from remaining live cells. When compared to CTRL
cells, 1
st gen and 2
nd gen dTc mediated significant
decreases in the level of CFSE fluorescence and hence
number of live tumor cells (Figures 4B,C). Having
demonstrated that the anti-KIT dTc were stimulated to
divide in vitro in response to KIT+ tumor and lyse KIT+
targets, we sought to measure the in vivo efficacy.
In vivo assessment of anti-KIT dTc
To determine the ability of anti-KIT dTc to traffic to, infil-
trate, and limit growth of established tumor, we utilized a
subcutaneous xenograft model. Human KIT+ GIST cells
were injected subcutaneously into immunodeficient mice
that were treated with tail vein injections of 1
st gen, 2
nd
gen, or unmodified anti-KIT dTc 7 days later. Tumor
measurements were performed in two dimensions (mm
2)
and are expressed as median percentage change relative to
the tumor size on initial day of treatment. IL2 therapy was
given along with dTc for some groups because IL2 is
known to enhance T cell function and may play a role in
tumor clearance. In a single repetition, significant
reductions in tumor growth were mediated by 1
st gen dTc
without IL2 (p=0.05) and 2
nd gen dTc (p<0.001) with IL2
(Figure 5A). When all data were pooled, both 1
st and 2
nd
gen dTc had a significant impact on tumor growth in the
absence of IL2 therapy. With IL2 support, 1
st gen dTc had
as i g n i f i c a n te f f e c t( p = 0 . 0 5 )w h i l e2
nd gen dTc (p=0.13)
demonstrated a favorable trend (Figure 5B). 1
st gen dTc
m a yb em o r er e l i a n to nI L 2t h a n2
nd gen dTc because the
presence of the co-stimulatory signal through the CD28
portion of the construct may reduce the dependence of 2
nd
gen dTc on cytokines such as IL2. Data is further
represented as tumor growth for each individual sample to
demonstrate the range of values (Figure 5C). Following
sacrifice, we harvested the tumors and confirmed the pres-
ence of adoptively transferred dTc and necrosis in animals
treated with 1
st or 2
nd gen dTc (Figures 5D and E).
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We have constructed a novel anti-KIT CIR that can be
utilized to reprogram human T cells to recognize and
kill KIT+ GIST tumors. The natural ligand for KIT, SCF,
conferred anti-tumor specificity for the anti-KIT CIR
and T cells were transduced with high levels of effi-
ciency. Our in vitro studies confirmed that anti-KIT dTc
proliferated and secreted IFNγ in response to two KIT+
GIST cell lines, one of which was established from a
GIST clinically resistant to kinase-inhibitor therapy with
imatinib. The dTc were also able to lyse KIT+ cells
in vitro. Using a xenograft model, we demonstrated that
systemic infusions of 1
st and 2
nd gen anti-KIT dTc
resulted in significant reductions in tumor growth rates.
Taken together, our initial study of anti-KIT dTc
supports their further development as a novel treatment
for KIT+ neoplasms, including those which have
developed clinical resistance to kinase-inhibitor therapy.
Success with the clinical use of dTc has been reported
for the treatment of chronic lymphocytic leukemia, mel-
anoma, and synovial cell sarcoma [11,17]. DTc may offer
a new therapeutic option for GIST treatment that can be
used alone or in combination with other therapies, in-
cluding TKIs. Imatinib has been reported to induce
regulatory T cell apoptosis and its efficacy was enhanced
by concurrent immunotherapy [18]. Adding imatinib to
anti-KIT dTc infusions may augment efficacy through fa-
vorable immunomodulation within the tumor micro-
environment, allowing the dTc to mediate enhanced
tumor cell lysis.
Our histologic studies confirmed that anti-KIT dTc
traffic to KIT+ tumors and mediate tumor necrosis after
intravenous infusion. Few CTRL T cells were seen within
the tumors following intravenous infusion, suggesting that
either preferential trafficking or intratumoral proliferation
accounted for the presence of anti-KIT dTc within the
GIST xenografts. Although we demonstrated dTc within
GIST xenografts, we speculate that the predominance of a
central memory phenotype (CD62L+CCR7+CD45RO+)
among anti-KIT dTc following production may have
promoted preferential migration to lymphoid tissue,
which we did not examine further [19,20]. Addition
of IL-15 and IL-21 to promote an effector phenotype
[21] may offer the potential of enhancing the efficacy
of anti-KIT dTc. The optimal production method and
dTc subsets for treatment of KIT+ tumors remain
to be determined.
Significant delays in tumor growth following a single
dTc infusion in our in vivo model support the poten-
tial utility of anti-KIT dTc for the treatment of GIST.
Yet, only one animal experienced a complete regres-
sion and several factors may have limited in vivo activ-
ity of the anti-KIT dTc. Multiple infusions may be
necessary to achieve complete regression of established
tumors, given that the efficacy of the anti-KIT dTc
seemed to wane 7 days following a single infusion.
When comparing the median tumor sizes at several
time points, a small number of outliers appeared to
have a significant impact on the analysis of the 2
nd
gen groups. In addition, the absence of a normal im-
mune cell repertoire in the immunodeficient mice may
have limited the extent of the anti-tumor effect
following dTc infusion. We speculate that tumor cell
lysis, antigen release, and the associated inflammatory
response may stimulate endogenous immunity which
may contribute to tumor regression. The implications
of a normal endogenous immune system for the
in vivo activity of anti-KIT dTc require clarification
through additional studies.
Several limitations of our data warrant consideration.
Our findings did not support a significant or consistent
benefit to either the presence of CD28 signaling in the
2
nd gen dTc or IL-2 infusion for the treatment of
established GIST xenografts. The addition of the CD28
moiety to other CIR constructs has been shown to en-
hance dTc persistence and lytic function, although
conflicting results have been reported [7,22,23]. The ab-
sence of a compelling advantage for the 2
nd gen dTc
compared to the 1
st gen in our model may be specific to
the anti-KIT constructs and further testing will be
required to explain the limited benefit of CD28 co-
stimulation. In vitro, it has been shown that exogenous
IL-2 was necessary in order for modified T cells to have
a marked effect on tumor growth [23]. We speculate
that immunodeficient mice did not show a significant
response to supplemental IL-2 due to their lack of en-
dogenous Treg that can deplete IL-2 from the environ-
ment [24]. Furthermore, Treg have been shown to
directly inhibit the induction of IL-2 mRNA, which
augments the requirement for exogenous IL-2 addition
(See figure on previous page.)
Figure 5 In vivo testing of human anti-KIT designer T cells. We used a subcutaneous xenograft model whereby GIST 882 cells were injected
subcutaneously into immunodeficient mice prior to treatment with human anti-KIT dTc. Median results from a single representative experiment
(A) and pooled data from 3 experiments (B) are shown. Activated CIR- T cells were used as negative controls. (C) Median tumor sizes at Day 5,
Day 10, and Day 15 post-infusion are indicated by horizontal bars along with individual tumor measurements represented by the data points. (D)
We performed immunohistochemistry (top row 10x, bottom row 40x) to detect tumor infiltrating CD3+ T cells (arrows). (E) Routine H&E was used
to assess the degree of tumor necrosis (asterisks) in mice treated with 1
st or 2
nd gen dTc, both with and without supplemental IL2 (left column
10x, right column 40x).
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http://www.translational-medicine.com/content/11/1/46[17]. We are also unable to exclude the possibility that
the modification of the T cells in some way altered their
intrinsic responsiveness to IL-2 in vivo.
Finally, our in vivo murine model might not have per-
mitted a full assessment of toxicity given that we utilized
the human SCF moiety in the CIR. Expression of the
KIT gene is essential for the development of normal
hematopoiesis, proliferation, and migration of primordial
germ cells and melanoblasts during embryogenesis as
well as for the development of gastrointestinal pace-
maker activity [16,25]. Although it may be reasonable to
address this concern in a phase I trial with a small num-
ber of patients, development of suitable animal model
prior to clinical studies would be preferable.
Conclusions
We have successfully produced anti-KIT dTc and have
demonstrated their capacity for recognizing and killing
KIT+ GIST cells. The present study establishes the basis
for further investigation of anti-KIT dTc for the treat-
ment of advanced GIST refractory to tyrosine kinase
inhibitors. Study of anti-KIT dTc function in the context
of an intact immune system will be informative, along
with more detailed characterization of the phenotype of
the 1
st and 2
nd gen dTc. A phase I clinical trial will be
required to demonstrate the safety of anti-KIT dTc in
addition to their potential efficacy.
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